Twitter IconLinkedIn logo for website footers

September 19 – 21, 2017
Boston, USA

Speakers

Expand/Collapse

Amanda Hart
Director, US Regional Liaison, Real World Informatics &Analytics
Astellas Pharma US

Amanda Hart has worked in the Pharmaceutical industry for over 15 years.  Her current role is Director, US Regional Liaison, Real World Informatics and Analytics at Astellas Pharma.   She supported the development of the RWI&A function and currently supports global teams across multiple therapeutic areas.  She develops and executes analytics to support the commercial perspective across the product value chain.  Amanda previously worked for Takeda Pharmaceuticals, developing the HR Analytics function and holding roles of increasing responsibility in Sales Analytics, Marketing Analytics and New Product Analytics.  Amanda holds a BA in economics from The University of Chicago and an MBA in marketing from DePaul University.

Day Two

Thursday September 21, 2017

12.15 | Unlocking the Power of Real World Evidence Data

Brett Davis
General Manager
ConvergeHEALTH by Deloitte

Brett is the General Manager of ConvergeHEALTH and a principal with Deloitte Consulting. In addition to his role at ConvergeHEALTH, Brett serves on the board of directors of the tranSMART Foundation, and the external advisory boards of both the University of Pennsylvania’s Center for Medical Ethics and Health Policy and the Jefferson School of Population Health. He was also a board member of the Personalized Medicine Coalition for six years. Prior to joining ConvergeHEALTH, Brett was the senior director for global business development and strategy at Oracle Health Sciences, and a business unit executive in IBM’s health care and life sciences business. Brett is a graduate of The Pennsylvania State University.

Day One

Wednesday September 20, 2017

10.15 | The Data Driven Shift to Value Based, Personalized Healthcare

Christoph Koenen
VP Development Lead
Bristol-Myers Squibb

Dr. Koenen is currently heading anticoagulation development in BMS. Christoph joined BMS in 2011 and has worked in different medical and development functions in Europe as well as in the US. He joined BMS from Novo Nordisk were his last position was Vice President and Head of Medical Affairs. During his 9 years with Novo Nordisk Christoph has worked on the development of several compounds for Novo Nordisk including three different insulin compounds. Before joining Novo Nordisk in 2002, Christoph worked for GlaxoSmithKline Inc. in London. While at GlaxoSmithKline, Christoph was responsible for the development of anti-diabetic compounds. Christoph received his medical degree from Ruprecht-Karls University School of Medicine in Heidelberg, Germany in 1994. He also holds a Master of Business Administration from Schiller International University.  In addition to attending Heidelberg Medical School, Christoph attended medical school in Johannesburg, South Africa, Basel Switzerland and Columbia, Missouri, USA. As a board certified internist and diabetologist, Christoph has researched the influence of ACE-Inhibitors on diabetic nephropathy, as well as the effect of insulin treatment on weight gain in obese type 2 diabetes patients.

Day One

Wednesday September 20, 2017

09.00 | Opening Keynote Panel Discussion: Defining the Value of RWE Through Advanced Analytics across the Continuum of Drug Development

Day Two

Thursday September 21, 2017

08.45 | Using RWD to Complement & Advance Scientific Insights

Dee Amanze
Director of Clinical Consulting
Saama Technologies

As Director of Clinical Consulting at Saama Technologies, Dr. Dee Amanze provides his expertise across Product Development, Solution Delivery and Positioning. With a PhD in Biomedical Research from University of Birmingham, England, he has conducted several years of post-doctoral research on various aspects of early embryonic development, with particular interest in genetics, cellular basis of morphogenesis and sperm-egg interactions. He brings over 10 years experience in clinical consulting, clinical market definition, clinical trials, real world evidence and longitudinal patient data analytics.

Day Two

Thursday September 21, 2017

09.45 | 5 Steps to Getting Maximum Value from Real World Data

Frank Zhang
VP Market Access - Global Strategy & US
Alnylam Pharmaceuticals

Frank Zhang is currently VP Market Access - Global Strategy and US at Alnylam Pharmaceticals, a Cambridge based company leading RNAi technology. Prior to Alnylam, Frank was the Head of Global Pricing and Market Access for Immunology and In ammation franchise of Celgene Corporation from June 2010 to Feb 2017. His responsibilities covered five key global functions for Celgene I&I, including Pricing and Market Access, Global Health Economics, Global Outcomes Research, Patient Reported Outcomes (PRO), and Strategic Data Analytics. With his leadership, Otezla was approved for pricing and reimbursement in over 20 countries within 2-year of global launch. Prior to Celgene, Frank led global Pricing and Health Economics for J&J’s Virology Franchise with successful launch of Incivo/Incivek and Intelence. He was US Outcomes Research lead for Concerta and Effexor in earlier part of his career. Frank is a physician by training with a Master of Public Health degree from Yale University.

Day One

Wednesday September 20, 2017

12.15 | How to Create a Comprehensive Evidence Generation Plan Throughout the Life Cycle to Optimize Pricing & Market Access Potentials

09.00 | Opening Keynote Panel Discussion: Defining the Value of RWE Through Advanced Analytics across the Continuum of Drug Development

James Harnett
Senior Director, Real World Data & Analytics
Pfizer

Dr. James Harnett is a Senior Director in Real World Data and Analytics (RWDnA) for Pfizer’s Patient Health & Impact organization.  Dr. Harnett has worked at Pfizer for over 15 years and supported establishing the RWDnA function.  He was previously Team Lead in Outcomes Research and a Market Access Lead.  He has conducted research across numerous therapeutic areas, currently focusing on oncology, vaccines, and inflammation & immunology, authoring over 30 peer-reviewed publications.  Dr. Harnett has received awards for innovation on external partnerships and advanced analytics and use of real world evidence for regulatory decision making.  He has a Doctor of Pharmacy degree and Master of Science degree in Clinical Epidemiology and Health Services Research.

Day One

Wednesday September 20, 2017

13.45 | Optimizing Access With Real-World Evidence

Josh Ransom
Head of Clinical Products
SHYFT Analytics

Josh is a Head of Clinical Products at SHYFT Analytics where he is co-leading development of new software-as-a-solution (SaaS) platforms for top pharmaceutical & biotech companies. In addition, he has served leading pharmaceutical, biotechnology, and medical device companies focusing on the application of Real World Evidence to both clinical and commercial challenges as well as launch and market access for personalized medicines and other emerging medical technologies. Prior to joining SHYFT, Josh was an Associate Director in Quintiles Consulting's Emerging Technology Strategy practice and a Precision Medicine subject matter expert. Prior to joining Quintiles, Josh was a Senior Associate with McKinsey & Company in their New Jersey office with a focus on innovation strategy and commercial strategy redesign.

Day One

Wednesday September 20, 2017

15.15 | The Development Hyperloop: Accelerating Clinical and Commercial Processes with Real World Evidence

Julie Locklear
VP & Head, Health Economics & Outcomes Research
EMD Serono

Julie Locklear, PharmD, MBA is Vice President for Health Economics & Outcomes Research (HEOR) at EMD Serono, Inc, a business of Merck KGaA, Darmstadt, Germany. Dr. Locklear joined EMD Serono, Inc. in January 2013. In this role, she is responsible for establishing the US Health Economics & Outcomes Research team within the Medical Affairs Organization. Leadership of a team responsible for developing, executing and disseminating the value evidence of EMD Serono's portfolio of specialty products in the areas of oncology, immuno-oncology, immunology, neuroscience, infertility, and endocrinology. Ensures US payer customer needs are aligned with cross-functional partners across the US and Global organizations. Leads a team of in-house HEOR researchers who generate value evidence as well as field-based HEOR team who interact with formulary decision makers. Her previous experience includes seven years as Global Payer Evidence Director at AstraZeneca Pharmaceuticals where her responsibilities focused on the development of successful global reimbursement dossiers across multiple therapeutic areas including inflammation, respiratory, neuroscience and autoimmune disorders. She has experience launching products, business development, market access, leading cross functional internal teams (direct and indirect management), external contract research organizations, and alliance management. Prior to AstraZeneca, she worked for Janssen Pharmaceutica in a variety of health economic roles including both in-house and customer facing. Dr. Locklear received her Doctor of Pharmacy from the University of Rhode Island and a Masters in Business Administration from Saint Joseph’s University. She currently sits on the board of Network for Excellence in Health Innovation (NEHI) and sits on a number of executive-level real-world evidence (RWE) roundtable discussions.

Day One

Wednesday September 20, 2017

14.15 | Using RWE to Support Outcome-Based Contracting & Pricing Models

09.00 | Opening Keynote Panel Discussion: Defining the Value of RWE Through Advanced Analytics across the Continuum of Drug Development

Day Two

Thursday September 21, 2017

16.30 | Chair’s Closing Remarks

08.30 | Chair’s Opening Remarks

Julie van Bavel
Director, Medical Policy – Access Research, Center for Observational & Real World Evidence (CORE)
Merck

Julie van Bavel has worked in the Pharmaceutical industry for almost twenty years in a variety of Access and Policy roles. Having recently moved to the US from Australia, she is currently part of the Center for Observational and Real World Evidence (CORE) at Merck. She has a broad range of experience working with government, non-profits and key opinion leaders in areas such as Health Technology Assessment, assessment of value, comparative effectiveness, and policy. She has worked in both single payer developed markets and multi-payer developing markets, bringing to the table a perspective informed by an appreciation of the differences, strengths and challenges of each. While in Australia, Julie led MSD’s Market Access team.  In that role she oversaw the completion of more than 40 reimbursement submissions and three reviews for the Pharmaceutical Benefits Advisory Committee (PBAC). She was an active Member of Medicines Australia’s Health Economic Working Group (HEWG), and speaker at ARCs Australia conference. In her current role, she is developing evidence for policy, focusing predominantly on systemic issues such as pricing and assessment of value. Julie has a Masters of Public Health from the University of Sydney and a Masters of Veterinary Science from the University of Melbourne.

Day One

Wednesday September 20, 2017

16.45 | Using Real World Data to Inform the Design of Outcomes-Based Risk Share Agreements

Jyotsna Mehta
Director, Economics Value Evidence & Outcomes
Alkermes

Jyotsna Mehta is Director, Economics Value Evidence and Outcomes  at Alkermes.  Her responsibilities include providing strategic HEOR capabilities and insights to maximize access and uptake at launch and throughout the lifecyle of Alkermes products.  Jyotsna has worked in the pharmaceutical industry since 2008, including positions of increasing responsibility at Astra Zeneca, Sanofi Aventis, EMD Serono in multiple therapeutic areas. Prior to this, she has worked at FDA and Harvard Medical School as a researcher for 8 years.  Jyotsna has an M.S. in Pharmacoeconomics and Pharmacoepidemiology and is a pharmacist by training . She has published widely in peer reviewed journals and made presentations to professional organizations and participated in panels and invited talks.

Day Two

Thursday September 21, 2017

09.15 | Platform Based Approaches in RWE – Approaches, Methodologies & Examples

Katya Tsaioun
Executive Director, Evidence-Based Toxicology Collaboration
Johns Hopkins Bloomberg School of Public Health

Dr. Tsaioun is a scientist and entrepreneur with focus on commercialization of technological innovations in ADME and safety assessment and interest in translation of science innovations into public policy. She spent most of her career developing and implementing ADME and safety assessment tools in drug discovery. In 2005 she became an entrepreneur and founded a company, Apredica, that developed, in-licensed and commercialized a number of in vitro ADME and toxicity tests, grew the company to a leader in the field and led a successful acquisition by a UK public company Cyprotex. She served on the Board of Cyprotex, managing the merged R&D team, as a CSO. Dr. Tsaioun currently serves on the scientific and advisory boards of biotech companies, charities, and wellness tech companies. Her current research interests are in public health, knowledge translation and implementation of evidence-based methods in healthcare, wellness/disease prevention and toxicology. Currently she an Executive Director of Evidence-Based Toxicology Collaboration at Johns Hopkins Bloomberg School of Public Health. She earned her PhD in Nutritional Biochemistry at Tufts University Friedman School of Nutrition Science and Policy. Her doctoral research focused on the role of vitamin K-dependent growth factor Gas6 in the developing and aging nervous system. She completed her post-doctoral training at Harvard Medical School, where she worked on discovery of novel trafficking mechanisms of dopamine transporter and cannabinoid receptor and their roles in drug dependence.

Day Two

Thursday September 21, 2017

13.45 | Adapting Evidence-Based Medicine Methods For Toxicity & Exposure Assessments

Kitty Rajagopalan
VP & Head Global Health Economics & Outcomes Research & Market Access
Sunovion Pharmaceuticals

Kitty Rajagopalan, B.S (Pharm), MS, PhD has over 24 years of experience in health economics and outcomes research across drugs, devices, and biologics. Her cross-therapeutic area HEOR leadership expertise spans a wide spectrum of diseases and conditions including but not limited to psychiatry, neurology, oncology, cardio-pulmonary, and autoimmune diseases.  She also has proven expertise in building and leading global and US health outcomes, pricing and economics (GHOPE) functions that help differentiate pipeline assets and inline brands across company portfolios. Her experience also includes successful interactions and negotiations with FDA, EMA (Global Healthcare Regulatory) and payor (US and Ex-US) bodies in securing PRO label claims, and successful market access through positive reimbursement guidance, and formulary inclusion/preferred status.   Kitty’s global geographic experience span includes US, Canada, Australia, Europe (including UK), Latin America and Asia, with specific emphasis on BRIC (Brazil, Russia, India, and China) Nations.  Some of her notable successes include: First in class QoL and PRO label claims; Medicare ‘New technology/pass-through reimbursement;  Positive reimbursement guidance from NICE, PBAC, other HTA bodies and US Public/Private payors and enabling device-related reimbursement legislation changes in Brazil. She owns multiple copyrights for patient reported outcomes instruments and has published over 80+ manuscripts in peer-reviewed journals. She also has presented over 600 scientific papers at meetings and is an invited speaker at DIA, ISPOR and other forums on health care topics as diverse as global reimbursement, HEOR methodologies, Patient Reported Outcomes in Clinical trials,  emergence of ACOs and role of HEOR.  

Day One

Wednesday September 20, 2017

16.15 | Utility of US Real World Evidence in Successful Global HTA Submissions

09.00 | Opening Keynote Panel Discussion: Defining the Value of RWE Through Advanced Analytics across the Continuum of Drug Development

Larry Pickett
Former VP & CIO
Purdue Pharma LP

Larry Pickett is the former Vice President and Chief Information Officer for Purdue Pharma LP.  At Purdue, Larry had responsibility for all information technology functions, including IT strategy, business process transformation, technology infrastructure, analytics and applications development. Based on an innovative “Big Data” analytics platform developed under his leadership, in 2016, investors from Wall Street and the City of London provided funding for a new startup.  The startup, RxDataScience Inc., for which Larry is CEO and Co-Founder, is responsible for bringing the capabilities of a unique Wall Street analytics technology to the broader pharmaceutical and healthcare industry.  Larry is also a founding member of the Westchester/Fairfield chapter of the Society for Information Management and is active with the Pharmaceutical Information Systems Association, an association of CIOs in the pharmaceutical industry. He is on various CIO Customer Advisory Boards and similar life sciences advisory boards. He has also served on committees within the Pharmaceutical Research and Manufacturers of America PhRMA). Before joining Purdue, he held senior IT positions with Merck, Glaxo Welcome, and GE. He earned his Bachelor’s degree from the University of North Carolina at Chapel Hill and MBA from the University of North Carolina at Greensboro.  

Day Two

Thursday September 21, 2017

11.30 | Panel Discussion: The Uptake of Real-World Analytics

Lixia Wang
Senior VP - Biometrics Health Economics & Outcomes Research
CTI Biopharma Corp

Lixia Wang, PhD, is the senior vice president of Biometrics and Health Economic Outcome Research at CTI BioPharma, a biopharmaceutical company.  Prior to CTI, she held various leadership positions at Novartis, Merck, and Cephalon where she led statistics and data analytics organizations in supporting drug development, reimbursement, and commercialization. Lixia received her PhD in Biostatistics from the School of Public Health at University of South Carolina. She has dedicated her professional career to apply analytical science to the decision making process, creating the operational excellent in drug development and commercialization. She has advocated collaboration among industry, academic and health authority and has initiated and supported projects in the collaboration.

Day One

Wednesday September 20, 2017

17.15 | RWD/RWE in the Life Cycle of Drug Development – Opportunities & Challenges

Nataraj Dasgupta
VP, Advanced Analytics
RxDataScience Inc.

Nataraj is the Vice President of Advanced Analytics at RxDataScience Inc. . Prior to his current role, he led the Data Science division at Purdue Pharma, L.P. and was responsible for the design, development and architecture of Purdue’s award-winning Big Data and Machine Learning Platform. Nataraj has been in the IT industry for more than 19 years and has worked in the technology divisions of Philip Morris, IBM, UBS Investment Bank and Purdue Pharma. At UBS, Nataraj held the role of Associate Director working with High Frequency & Algorithmic Trading technologies used by investment banks and hedge funds on Wall St and other financial centers across the world. The finance industry has been implementing “Big Data” systems for many decades and has had a mature set of tools that has permitted traders and quants to analyse large volumes of trading-related data in the order of milliseconds. Despite Pharma's ubiquitous reliance on more traditional enterprise systems, Nataraj and the Systems Development & Analytics group led by Sayee Natarajan, chose to instead leverage technologies that were exclusively used in the financial domain and never before in a healthcare setting to analyse terabyte-scale medical and pharmaceutical datasets. The effort led to a radically simple platform built using trading specific tools which were less expensive than conventional “Big Data” platforms, yet orders of magnitude faster in data processing capabilities facilitating tasks to complete in seconds compared to days in the existing and more popular Pharma enterprise systems. The platform received a wide recognition as one of the most advanced big data solutions for healthcare and led to several awards, including the recognition of Purdue Pharma as one of the top 25 most innovative technological divisions in the US by Information Week. In 2016, investors from Wall Street and the City of London provided funding for a new startup, RxDataScience Inc. responsible of introducing the capabilities of this unique architecture to the broader healthcare industry.

Pre Conference Bootcamp

Tuesday September 19, 2017

09.00 |

Paul S. Barth
CEO
Podium Data

Dr. Paul Barth is founder and CEO of Podium Data, creator of the industry-leading Podium data lake software platform that is redefining enterprise data management. He has spent decades developing advanced data and analytics solutions for Fortune 100 companies, and is a recognized thought-leader on business-driven data strategies and best practices. Prior to founding Podium Data, Paul co-founded NewVantage Partners, a boutique consultancy advising C-level executives at leading banking, investment, and insurance firms. In his roles at Schlumberger, Thinking Machines, Epsilon, Tessera, and iXL, Dr. Barth led the discovery and development of parallel processing and machine learning technologies to dramatically accelerate and simplify data management and analytics. Paul holds a PhD in computer science from the MIT, and an MS from Yale University.

Day Two

Thursday September 21, 2017

12.15 | Unlocking the Power of Real World Evidence Data

Rajneesh Patil
Senior Director - Risk Based Monitoring & Analytics
QuintilesIMS

Rajneesh Patil is a Senior Director with Quintiles’. His expertise spans process design, project portfolio management, clinical data management, risk based monitoring and predictive analytics for clinical trials industry. Rajneesh is a gold medalist in Dental Surgery from India with Foundations certificate in Public health from Australia. He is a certified Six Sigma Greenbelt and an MBA with Project Management Professional (PMP®) certification from PMI, USA.

Day Two

Thursday September 21, 2017

11.00 | Predictive Analytics & Use of Real-World Data Analytics for Trial Design

Sandy Balkin
Senior Director, Global Insights & Analytics
Sanofi US

Sandy D. Balkin, Ph.D. is Senior Director, Global Insights & Analytics with Sanofi. His responsibilities include the identification of opportunities and risks associated with commercial products, pipeline candidates and new business opportunities.  Sandy also leads the development of innovative solutions to provide actionable insights using patient-level data combining modern pre-analytic data staging and preparation with advanced statistical and machine learning methods.  Recent applications include novel, quantitative approaches to market sizing, forecasting by severity, rare disease detection, specialty product tracking and physician targeting. Sandy brings almost 20 years of pharmaceutical industry and investment research experience building and leading forecasting and business analytic functions at companies including Pfizer, Boehringer-Ingelheim, and Aptus Health.

Day Two

Thursday September 21, 2017

15.45 | Panel Discussion: Addressing the Challenges in Successfully Leveraging Real-World Analytics

15.15 | Understanding & Reacting to the Patient Journey Through Real- World Evidence

Sebastian Schneeweiss
Vice Chief, Division of Pharmacoepidemiology & Pharmacoeconomics
Brigham & Women’s Hospital

Sebastian Schneeweiss is Professor of Medicine and Epidemiology at Harvard Medical School and Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics of the Department of Medicine, Brigham and Women’s Hospital, a world-leading research and training center. His research is funded by multiple NIH, PCORI, and FDA grants and focuses on the comparative effectiveness and safety of biopharmaceuticals. He has developed analytic methods to improve the scientific validity of epidemiologic analyses using complex longitudinal healthcare databases particularly for newly marketed medical products. Applying such methods transparently and in rapid cycles for sequential medication effectiveness monitoring is the overarching theme of his research. His work is published in >300 articles, many of them in high-ranking journals. He is Aetion Inc.’s Science Lead were he develops a worldwide network of rapid-cycle analytics platforms that produces evidence fit for decision making in healthcare. Dr. Schneeweiss is Director of the Harvard-Brigham Drug Safety Research Center funded by FDA/CDER and Co-Chair of the Methods Core of the FDA Sentinel program. He is voting consultant to the FDA Drug Safety and Risk Management Advisory Committee and was inaugural member of the Methods Committee of the Patient Centered Outcomes Research Institute. He was President of the International Society for Pharmacoepidemiology, inaugural member of the PCORI Methods Committee and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology. At Harvard he teaches courses on Database Analytics for Pharmacoepidemiology and on Effectiveness Research in Longitudinal Healthcare Databases among others. He received his medical training at the Ludwig-Maximilians University of Munich and his doctoral degree in pharmacoepidemiology from Harvard.

Day Two

Thursday September 21, 2017

14.15 | The Rise of Analytic Tools in Real World Data Analytics: A Case-Study

11.30 | Panel Discussion: The Uptake of Real-World Analytics

Tehseen Salimi
Head of Medical Affairs for Primary Care & Women’s Health
Merck

Dr. Tehseen Salimi, MD, MHA, is currently serving as Head of Medical Affairs for Primary Care & Women’s Health at Merck. Prior to Joining Merck she has served in Medical Affairs leadership roles within several Pharmaceutical organizations including Roche , Sanofi , AstraZeneca & Trevena  Prior to joining the Pharmaceutical industry she served in leadership positions within managed care organizations, including Cigna and Fallon Health care. Dr. Salimi is a Healthcare Executive with over 25 years of experience leading transformative patient-centric initiatives to bridge the evidence & value gaps. Her leadership developed in complex and rapidly changing environments, is backed with strong tenure in managed care (US Payer) and global pharmaceutical arenas. Her work to develop evidence based frameworks including a model for integrating medical value into portfolio valuation & Medical Affairs strategy & planning process has been critical for customer-centric transformation . During her tenure, Dr. Salimi was honored with several awards, including the Hippocratic award for connecting Science with Medical Practice , the Physician’s Recognition Award for Best Outcomes and the Superior Achievement Award at Cigna. She was also featured in the 1998 annual report of the National Committee for Quality Assurance (NCQA) for the Best Practice Quality Improvement Initiative. She attributes her success to commitment to Patient care, perseverance, and dedication to Innovation & learning. Dr.Salimi is a physician by training and obtained her Preventive medicine fellowship  from University of Massachusetts and a Masters in Health administration from a joint degree program at Clark and UMass .

Day One

Wednesday September 20, 2017

17.45 | Chair’s Closing Remarks

09.45 | Keynote Session: Real-World Analytics & Value Generation – Successfully Bringing to Market & Commercializing Drugs

08.45 | Chair’s Opening Remarks

Tom Hughes
Senior Director, Health Economics & Outcomes Research
Avanir Pharmaceuticals

Dr. Hughes began his career as a clinical pharmacist at Tucson Medical Center.  After receiving his PhD from The University of Arizona he has worked in pharmaceutical industry for over 25 years.  He spent 17 years at Eli Lilly & Company, starting as a HEOR researcher, then led Lilly’s Global Health Outcomes group, and finally led Lilly’s US affiliate Managed Markets Neuroscience group.  Dr. Hughes worked in a consulting group for UnitedHealthcare for 5 years, helping pharmaceutical companies understand what is necessary to achieve commercial success.  He was an independent consultant in the HEOR and market access space on a global basis for two years.  Dr. Hughes joined Avanir in September 2016 to lead their HEOR group.

Day One

Wednesday September 20, 2017

11.45 | The Right Answer to the Wrong Question is Not Commercially Relevant

Day Two

Thursday September 21, 2017

11.30 | Panel Discussion: The Uptake of Real-World Analytics

Wanmei Ou
Director, Precision Medicine & Data Science, Center for Observational & Real World Evidence (CORE)
Merck

Wanmei Ou is currently a Director in Precision Medicine and Data Science at Merck’s Center for Observational and Real-world Evidence (CORE) department. At Merck, She has dual responsibilities to accelerate target discovery using real-world data and to address the pricing and affordability issues of medicine through value-based payment models. In this role, she develops and executes analysis plans for observational studies across the company’s product franchises. Prior to this, Wanmei lead a technology team at Oracle to develop a genomic-focus application, which has been deployed as a foundation component by many leading healthcare institutes in support of their precision medicine initiatives. Wanmei is a member of the Health IT Standards Committee in the Office of the National Coordinator for Health Information Technology, part of the U.S. Department of Health and Human Services. In this role, she recommended standards, implementation, and certification criteria for health IT infrastructure. Wanmei obtained a Ph.D. degree from Massachusetts Institute of Technology with focus on biomedical imaging.

Day One

Wednesday September 20, 2017

16.45 | Using Real World Data to Inform the Design of Outcomes-Based Risk Share Agreements

Day Two

Thursday September 21, 2017

15.45 | Panel Discussion: Addressing the Challenges in Successfully Leveraging Real-World Analytics